Clinical trial center of National Cancer Center of China. We have approved a total of 1051 registered clinical trials.In 2022our center initiated121 registered clinical trials,including 107 novel drug clinical trials.The proportion of early phase tials (Phaseland Phase II) has exceeded 60%，which also indicates that domestic clinical trials have stepped into a more cutting-edge exploration stageThe proportion of international multicenter studies has increased significantly,nine of which were initiated by Chinese companies. It indicates the globalized development of local biomedical industry.Of all multicenter IND trials conducted this year, our hospital led 66 as the leading unitaccounting for 65%.Twelve international multicenter registered trials were led by our investigators as NPI or domestic lead, including 5 international multicenter phaseIstudies,all for the treatment of solid tumors. In the past five years,investigator-initiated trials(llTs)have achieved rapid growth. In 2022 researchers initiated 466 studiesincluding 109(23%)multi-center projects led by our hospital reflecting that the scale and quality of IIT have been greatly improved.In terms of research types,observational clinical research,translational medicine research and drug clinical trials accounted for the largest proportions as 102100 and 81 respectively. In 202260 investigator-initiated trials were focused on multi-disciplinarytreatmentshowing researchers' active exploration of multidisciplinary anti-cancer treatment.We have implemented homoaeneous manaaement of clinical researchformulated norms and procedures for research,and strictly implemented the clinical trial registration and filing requirements of the National Health Commission. In 2022,we became one of the first batch of undertaking units of the National Quality Evaluation and Promotion Center for Clinical Research.